The popular type 2 diabetes drug Onglyza, also known as saxagliptina, has been linked with a significantly increased risk of heart failure.
Two popular type-2 diabetes drugs are in the news after the FDA warned this week that patients taking them may face higher risks of heart failure.
The new warning, issued Tuesday, focuses on the DPP-4 inhibitors Onglyza (saxagliptin), sold by AstraZeneca, and Nesina (alogliptin), sold by Takeda. Together, these drugs are prescribed more than 3 million times each year.
They rank among the most-prescribed drugs in the United States each year with over 20 million prescriptions. However, popular type 2 diabetes meds known as DPP-4 inhibitors now carry a new risk according to the FDA.
Last week, the agency issued a safety announcement advising that dipeptidyl peptidase-4 (DPP- 4) inhibitors can cause severe joint pain, and ordered that new products carry an additional warning on their label.